CD40 – CD40L Pathway
CD40 is a member of the TNF receptor family expressed by antigen-presenting cells (APCs) and B cells whereas its ligand, CD40L (CD154), is expressed by activated T cells. Interaction between CD40-CD40L stimulates cytokines secretion of B cells with subsequent T cell activation and antitumor immunity. This T cell priming effect of the CD40-CD40L pathway might be a useful approach in anticancer immunotherapy.
LIT: Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists: G.L. Beatty, et al.; Expert Rev. Anticancer Ther. 17, 175 (2017) • Multiple effects of CD40-CD40L axis in immunity against infection and cancer: A. Ara, et al.; Immunotargets Ther. 7, 55 (2018)
NEW: CD40L (human) ELISA Kit - Biomarker for Autoimmune Diseases & Cancers
The CD40L (human) ELISA Kit (Prod. No. AG-45B-0018) is a sandwich ELISA for specific quantitative determination of human soluble CD40L in serum, plasma and cell culture supernatants. This ELISA Kit shows a very high specificity and sensitivity (20pg/ml).
B Cell Expansion: Highly Potent B Cell Activators and T Cell Priming Reagents
CD40 activation tools can be used to expand B cells, which, as antigen-presenting cells (APCs), are as effective as dendritic cells and promises to streamline the generation of antitumor CD8+ T cells. Several studies show that usage of the agonistic anti-CD40 antibody (FGK45) (Prod. No. AG-20B-0036PF) and MultimericCD40L (Prod. No. AG-40B-0010) are strong stimulators of antitumor immunity.
LIT: R.S. Kornbluth, et al.; Int. Rev. Immunol. 31, 279 (2012) • K.T. Byrne & R.H. Vonderheide; Cell Rep. 15, 2719 (2016)
POTENT CD40L (human) (multimeric) (rec.) (Prod. No. AG-40B-0010)
Figure: CD40L (human) (multimeric) (rec.) (Prod. No. AG-40B-0010) does not need an enhancer to induce B cell activation.
NEW CD40L (human) (multimeric) (rec.) (Certified Serum Grade) (Prod. No. AG-40B-0010CSG)
Figure: CD40L (human) (multimeric) (rec.) (Certified Serum Grade) (Prod. No. AG-40B-0010CSG) does not need an enhancer to induce B cell activation.
POTENT anti-CD40 (mouse), mAb (FGK45) (Prod. No. AG-20B-0036)
Figure: Systemic immune activation by CD40 ligation. Mice were sacrificed on day 8 after daily treatment on day 4-7 with FGK45 or control. FGK45 treatment elevated splenocyte numbers. *P < 0.005. Data represent mean ± SD for three to four mice per group.
Biologically Active CD40 and CD40L Proteins
|CD40 (human):Fc (human) (rec.)||AG-40B-0083||HEK 293 cells||<0.01EU/µg||Human, Mouse|
|CD40 (human):Fc (human) (rec.)||CHI-HF-210CD40||CHO cells||<0.06EU/µg||Human|
|CD40 (human)-muIg Fusion Protein||
|CD40L (mouse) (multimeric) (rec.)||
|CHO cells||<0.01EU/µg||Human, Mouse|
|CD40L (human) (multimeric) (rec.)||
|CD40L (human):Fc (human) (rec.)||CHI-HF-210CD40L||CHO cells||<0.06EU/µg||Human|
|CD40L (human)-muCD8 Fusion Protein||
|CD40L (rat) (multimeric) (rec.)||AG-40B-0107||CHO cells||<0.02EU/µg||Human, Mouse, Rat|
VALIDATED Antibodies for CD40 and CD40L Research
|CD40 (mouse), mAb (FGK45) (PF)||AG-20B-0036PF||Rat IgG2a||FACS, FUNC||Mouse|
|CD40 (human), mAb (BE-1)||
|Mouse IgG1||FACS, FUNC, IP||Human|
|CD40 (human), mAb (EA-5)||
|Mouse IgG1||FACS, FUNC||Human, Rat|
|CD40L (human), mAb (rec.) (blocking) (hu5c8)||AG-27B-6002PF||Human IgG1κ||FUNC, WB||Human, Dog|
|CD40L (human), mAb (24-31)||
|Mouse IgG1||FACS, FUNC, IHC, WB||Human, Primate|